According to a Fox news report, more people die in America every year from prescription drug abuse than die from heroin and cocaine combined.  This leads us to the questions:

1. Are doctors over prescribing?
2. Are doctors closely monitoring drug usage of patients?
3. Are people illegally obtaining prescription drugs?

According to the Centers for Disease Control, most people who die from prescription drug overdose are taking someone else’s medicines, medicines that we left in the medicine cabinet, medicines that were given to a friend or a relative, maybe innocently, maybe maliciously.

In a study done by the CDC it was found that enough narcotics are prescribed every year to medicate each and every adult in America every day for a month.

Thomas Frieden, Director of the CDC, has said “It’s astonishing.  When I went to medical school, we were incorrectly assured, don’t worry, if patients have short-term pain, they won’t get hooked.  That was completely wrong, and a generation of doctors, patients, and families have learned that’s a tragic mistake.”

Although many states have passed new laws to monitor the prescribing of narcotic painkillers, the death rate due to this issue remains high.

A Sheriff of Pinella County in Florida, calls this issue widespread.  “This problem crosses all walks of life, crosses all socio-economic classes.  Crosses all races and gender, national origin, and age”, he said.

Topiramate (brand name: Topamax) is used to treat epileptic seizures and prevent migraines. However, the drug presents a risk of  birth defects in children born to mothers taking the drug.

As a result, the FDA has required that Topamax carry a stronger warning to alert pregnant women of the risks regarding taking the drug while pregnant.

According to the research, infants who were exposed to Topamax during pregnancy, specifically the first trimester, had an increased risk of developing cleft lips or cleft palates. If you took topiramate during pregnancy and delivered a child with an oral birth defect, you may be entitled to monetary damages.

Topamax Pregnancy Guidelines
Topiramate (brand name: Topamax) presents a risk of birth defects in children born to mothers taking the drug. As a result of this risk, the FDA released new Topamax pregnancy guidelines:

• Women of childbearing age should speak with their doctors about alternate treatment options, to limit the use of Topiramate during pregnancy
• Women of childbearing age who continue treatment with Topamax should use an effective birth control method
• Before beginning Topamax, women should speak with their doctor if they are pregnant or plan to become pregnant
• Women who become pregnant while taking Topamax should speak with their doctor immediately
• Women, even those who are pregnant, should not stop treatment with the drug before speaking with their health care professional

Due to the recent information regarding Topamax and pregnancy, women who took Topiramate during pregnancy and delivered a child with a cleft palate or cleft lip may have legal recourse. A Topamax lawsuit would allow women the opportunity to recover the cost of medical bills and other damages resulting from their child’s Topamax birth defects. To find out if you can participate in a Topamax lawsuit, complete our no cost case review form with details of your Topamax pregnancy side effects.

The popular painkillers Darvon and Darvocet (propoxyphene) have been pulled from the market because of their association with serious or even fatal heart rhythm abnormalities.

The US Food & Drug Administration (FDA) is also asking the manufacturers of generic propoxyphene-containing products to remove those products from the market.

Darvon and Darvocet are both made by Xanodyne Pharmaceuticals Inc. Propoxyphene is an opium-derivative used to treat mild to moderate pain. First approved by the FDA in 1957, propoxophene is sold by prescription under various names both alone (e.g., Darvon) or in combination with acetaminophen (e.g., Darvocet).

The US Food and Drug Administration has since reviewed the data from a recent study, which show that, even when taken at recommended doses, propoxyphene causes significant changes to the electrical activity of the heart. These changes, which can be seen on an electrocardiogram (ECG), can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death, the FDA said.

The available data also indicate that the risk of adverse events for any particular patient (even patients who have taken the drug for many years) is subject to change based on small changes in the health status of the patient, such as dehydration, a change in medications, or decreased kidney function, the agency said. As a result of these data, combined with other information, including new epidemiological data, the agency concluded that the risks of the medication outweigh the benefits.

Watson Pharmaceutical is recalling more of their fentanyl pain patches because of their tendency to leak harmful fentanyl gel.

The manufacturer is recalling the 75mcg/hr fentanyl transdermal system patches sold in the US from wholesalers and pharmacies. These defective drug patches are used to manage persistent chronic pain that requires constant treatment with opioids.

The recalled patches in particular are from lot number 92461850 and have an expiration date of August 31, 2009. These patches were shipped to customers between January 30, 2008 and March 19, 2008.

According to Watson, some of the patches in this lot have been leaking fentanyl gel and exposing it to patients or caregivers. Fentanyl gel is a highly addictive opiate that is 80 times more potent than morphine. Direct exposure can cause serious effects such as trouble breathing, extreme tiredness, confusion, or death.

Ethex Corporation has expanded its recall of morphine tablets on June 16, 2008. The recalled tablets potentially contain twice the dose of morphine that is on the prescription drug label.

Ethex Corporation originally recalled a single lot of morphine tablets on June 9, 2008. The recall has been expanded to include both 60 mg and 30 mg lots of extended release morphine tablets.

The recall expansion is being described as a precaution by Ethex Corporation. There have not been any reports of adverse reactions linked to the tablets.

Serious adverse reactions can develop due to an overdose of an opioid medication, like morphine. Symptoms of an opioid overdose include respiratory distress, low-blood pressure and hypotension.

The Food and Drug Administration (FDA) has listed the following recalled lots: 30mg Tablet/NDC # 58177-320-04: Lots 75090, 77846, 77847, 80048, 83320, 89661, 89665, 90252 through 90258, and 93284 and 60mg Tablet/NDC # 58177-330-04: Lots 91762 (previously reported), 75091, 75092, 77848 through 77851, 82517, 82518, 83333, 83817, 83862, 84111, 84112, 84315, 84900, 85326, 85335, 85807, 86270 through 86276, 87723, 87939, 88007, 89083, 89668, 89669, 89821, 90260 through 90272, and 91763 through 91765.

Defective drug attorneys are working to prevent the serious illnesses and injuries that can result from faulty prescription drugs.

ETHEX Corporation is recalling one lot of 60 mg morphine sulfate tablets due to a risk of overdose. The tablets were manufactured with double the dose of morphine sulfate that is on the label, which could cause serious adverse reactions.

The lot affected by the recall is number 91762. No additional lots are being recalled.

The morphine tablets were released between April 15 and April 27, 2008. They are under the ETHEX label.

As with all opioid medication, the consequences of an overdose can be fatal. An overdose of morphine may result in difficulty breathing and lowered blood pressure.

To this date, the U.S. Food and Drug Administration (FDA) has not received any reports of adverse side effects.

Defective drug attorneys are working to help prevent serious consequences of faulty prescription medication by holding drug manufactures responsible for their negligence.

University of Washington professors have published an article in the Journal of the American Medical Association that shows that the makers of Vioxx were well aware of the drug’s dangers before the major recall.

The article, which was published on Tuesday, April 15, 2008, shows that Merck knew about the dangers of Vioxx in 2001. Merck had internal knowledge that the patients enrolled in clinical trials were dying at three times the rate of the patients who were on placebos.

The article asserts that Merck minimized the actual number of deaths that resulted from Vioxx and withheld information from federal officials.

An attorney for Merck claims that the pharmaceutical company disclosed all documents to federal officials.

Vioxx was prescribed for arthritis and pain management. Merck promoted the drug as a safer alternative to aspirin. A major recall of Vioxx was issued in 2004 after numerous reports of serious illness and death were attributed to the drug. Data was submitted to the United States Food and Drug Administration as early as 2000 regarding the dangers associated with Vioxx.

Defective drug attorneys are working on cases in which serious illness and fatalities have occurred due to prescription drugs like Vioxx.

A newly released report claims that pharmaceutical company Merck engaged in various forms of scientific deception to downplay risks of the painkiller Vioxx and promote the drug’s sale.  Merck disguised in-house studies to appear to have been conducted by independent scientists at medical schools, according to a report published in the Journal of the American Medical Association.  Information for the report was gathered using thousands of documents uncovered during Vioxx-related lawsuits.

On March 25^{th, California regulators delayed the electronic tracking of prescription drugs for two years. The California State Board of Pharmacy voted 12-0 to allow prescription drug manufacturers, distributors and pharmacies an additional two years to begin electronically tracking prescription drugs from the manufacturer to the patient.The requirement was already delayed by the California State Legislation in 2007. Now, the pharmaceutical industry has until January 1, 2011. The delay is intended to allow the pharmaceutical industry time to set up computer systems that would comply with the first ever requirement to track prescriptions.}

The requirement was instituted in California after a recall of fake Lipitor.

There are defective drug attorneys currently working on cases that involve the serious and fatal illnesses that result from defective drugs.

The United States Food and Drug Administration (FDA) announced on March 14^{th that it is taking action to stop the import of Heparin into the United States. The active ingredient of Heparin is manufactured by Scientific Protein Laboratories LLC., which has headquarters in both Wisconsin and China.}

A major recall of Heparin was announced in January, 2008. Since then, hundreds of allergic reactions and at least 19 deaths have been reported in association with Heparin use.

A spokesperson for the FDA has announced that since the end of February, no new deaths have been reported due to adverse reactions to Heparin.

The Heparin that is being stopped at the borders is manufactured by Baxter International, Inc. of Wisconsin. Baxter reports that they have not isolated the contamination, so it cannot determine if the contaminated Heparin was manufactured in their Chinese facility.

Defective drug attorneys are currently at work to help those who have faced devastating consequences due to contaminated Heparin.